Pharvaris N.V., a biopharmaceutical company, plans to offer $150 million of ordinary shares in a public offering to fund research, development, and commercialization expenses for its bradykinin-mediated disease treatments. The underwriters may have an option to purchase additional shares, and Morgan Stanley, Leerink Partners, and others are serving as joint book-running managers. The offering is subject to market conditions. Interested investors can obtain more information from the SEC’s website or the underwriters. Pharvaris aims to develop oral therapies for angioedema attacks and is currently evaluating a Phase 3 study for the prevention and treatment of hereditary angioedema attacks.

Read more at GlobeNewswire: Pharvaris Announces Proposed Public Offering of Ordinary